Ponjee G A, de Rooy H A, Vader H L
St. Joseph Hospital, Clinical Laboratories, Veldhoven, The Netherlands.
Acta Endocrinol (Copenh). 1991 Apr;124(4):411-6. doi: 10.1530/acta.0.1240411.
Serum 5 alpha-androstane-3 alpha,17 beta-diolglucuronide (3 alpha-AdiolG) levels were measured and the degree of hirsutism was scored in female outpatients complaining of excessive hair growth before and during treatment with cyproterone acetate. In a group of 16 patients with idiopathic hirsutism and in a group of 9 patients with either polycystic ovary syndrome and hirsutism or 21-hydroxylase deficiency and hirsutism, the serum 3 alpha-AdiolG levels were significantly increased (p less than 0.01) as compared with the serum 3 alpha-AdiolG level in a control group of 13 apparently healthy women: 3 alpha-AdiolG levels, median (range), being 5.3 (2.3-7.8) nmol/l, 8.5 (4.1-10.4) nmol/l, and 2.9 (1.5-5.2) nmol/l, respectively. In contrast to a previous report, no correlation was found between the serum 3 alpha-AdiolG levels and the Quetelet Index (N = 18, R = 0.42, p greater than 0.05), indicating an apparent ineffectiveness of the excessive androgen turnover in fat tissue. The use of the anti-androgen drug cyproterone acetate alone or in combination with ethinylestradiol in reverse sequential therapy did lower the 3 alpha-AdiolG levels significantly (p less than 0.01) together with a significant decrease (p less than 0.01) in hirsutism score. From the results of this study we therefore conclude that 3 alpha-AdiolG can be used as a parameter for peripheral androgen action before and during treatment with anti-androgens.
对主诉毛发过度生长的女性门诊患者在醋酸环丙孕酮治疗前及治疗期间测定血清5α-雄烷-3α,17β-二醇葡萄糖醛酸苷（3α-二醇葡萄糖醛酸苷，3α-AdiolG）水平，并对多毛症程度进行评分。在一组16例特发性多毛症患者以及一组9例患有多囊卵巢综合征伴多毛症或21-羟化酶缺乏伴多毛症的患者中，与13名外表健康女性组成的对照组相比，血清3α-AdiolG水平显著升高（p<0.01）：3α-AdiolG水平，中位数（范围）分别为5.3（2.3 - 7.8）nmol/l、8.5（4.1 - 10.4）nmol/l和2.9（1.5 - 5.2）nmol/l。与之前的一份报告相反，未发现血清3α-AdiolG水平与体重身高指数之间存在相关性（N = 18，R = 0.42，p>0.05），这表明脂肪组织中雄激素过度转化明显无效。单独使用抗雄激素药物醋酸环丙孕酮或与炔雌醇联合进行反向序贯治疗确实显著降低了3α-AdiolG水平（p<0.01），同时多毛症评分也显著降低（p<0.01）。因此，从本研究结果我们得出结论，3α-AdiolG可作为抗雄激素治疗前及治疗期间外周雄激素作用的一个参数。
